局部前列腺癌大分割与剂量增量放疗的疗效与耐受性:系统综述与荟萃分析
该系统综述与荟萃分析纳入25项随机对照试验共12479例临床局限期前列腺癌患者,评估大分割与剂量增量放疗方案的疗效与安全性。外照射联合近距离放疗或局部增量与转移无生存期显著改善相关(HR 0.76,95%CI 0.6-0.95,p=0.016);大分割生化复发无生存期有数值改善但未达统计学显著(HR 0.88,95%CI 0.76-1,p=0.058)。
要点
- 外照射联合近距离放疗或局部增量与标准放疗相比显著改善转移无生存期。
- 大分割生化复发无生存期呈数值改善但未达统计学显著,MFS和OS无显著差异。
- 中度大分割急性≥2级胃肠道不良事件轻度增加,超大分割急性≥3级泌尿生殖不良事件增加。
核心结论
- 剂量增量(联合近距离放疗或局部增量)与转移无生存期显著改善相关,支持在高危患者中用于改善生存。
- 大分割可缩短治疗时间,并可能与疾病控制潜在改善相关。
研究设计与样本
- 系统综述与荟萃分析(PROSPERO注册号CRD42024601045),检索MEDLINE、Embase、Web of Science、CENTRAL和Google Scholar,检索日期2025-06-15。
- 纳入双臂等效2 Gy分次剂量(EQD2)≥70 Gy的随机对照试验,共25项RCT、12479例临床局限期前列腺癌患者,采用随机效应模型合并数据并以森林图呈现,使用Cochrane RoB 2工具评估偏倚风险。
主要发现
- 外照射联合近距离放疗或局部增量对比标准放疗,转移无生存期显著改善(n=1468,HR 0.76,95%CI 0.6-0.95,p=0.016)。
- 包含两项延长随访研究的敏感性分析提示可能的OS获益(n=897,HR 0.75,95%CI 0.6-0.95,p=0.016)。
- 15项试验(n=10220)评估大分割的BRFS,呈小幅数值改善(HR 0.88,95%CI 0.76-1,p=0.058),但EQD2模型未能很好解释,MFS和OS无显著差异。
- 中度大分割急性≥2级胃肠道不良事件轻度增加,超大分割急性≥3级泌尿生殖不良事件增加,晚期不良事件无显著差异。
关键数值与推荐
- 纳入标准要求双臂EQD2≥70 Gy。
- 剂量增量分析中患者分配相关偏倚风险存在担忧,开放标签设计影响不良事件报告。
临床怎么用
- 剂量增量(联合近距离放疗或局部增量)可作为高危患者改善生存的治疗选择。
- 大分割可用于缩短治疗时间,并可能带来疾病控制的潜在改善。
- 采用中度大分割时需关注急性胃肠道不良事件,采用超大分割时需关注急性泌尿生殖不良事件。
局限性
- 剂量增量分析中患者分配相关偏倚风险存在担忧。
- 开放标签研究设计影响不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this systematic review and meta-analysis (PROSPERO: CRD42024601045), we evaluated the efficacy and safety of hypofractionated and dose-boosted radiotherapy fractionation schedules in patients with clinically localised prostate cancer. We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar on 2025-06-15 for randomised controlled trials (RCT) using equivalent doses in 2 Gy fractions (EQD2) ≥ 70 Gy in both arms, with outcomes including biochemical recurrence-free survival (BRFS), metastasis-free survival (MFS), overall survival (OS), and rates of grade ≥ 2/≥3 adverse events (AEs). Data were pooled using random-effects meta-analyses and presented in forest plots. Risk-of-bias (RoB) was assessed using the Cochrane RoB 2 tool. We identified 25 RCTs involving 12,479 patients. Combining external beam radiotherapy with brachytherapy or with focal boost was associated with significant MFS improvement (n = 1468, hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.6-0.95, p = 0.016) compared to standard radiotherapy. A sensitivity analysis including two studies with extended follow-up suggested possible OS benefit (n = 897, HR: 0.75, 95% CI: 0.6-0.95, p = 0.016). BRFS was evaluated in 15 trials testing hypofractionation (n = 10220). We found a small numerical improvement (HR 0.88, 95% CI 0.76-1, p = 0.058), though not well explained by the EQD2 model, and no significant differences in MFS or OS. Acute grade ≥ 2 gastrointestinal AEs were modestly increased with moderate hypofractionation, and acute grade ≥ 3 genitourinary AEs were increased with ultra-hypofractionation, without significant differences in late AEs. Primary limitations included concerns regarding RoB associated with patient allocation in dose-boost analysis, and impact of open-label study designs on AE reporting. These findings support the use of dose-boosting as a means to improve survival in high-risk patients, and hypofractionation as a method to reduce treatment time associated with a potential improvement in disease control.
引用
- Miszczyk M, Sohoni N, Smani S, et al. Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2026. PMID: 41713502. doi:10.1016/j.radonc.2026.111445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。